Specialty Pharma: Guide to Success at the New FrontierDecision ResourcesMay 31, 2007 27 Pages - SKU: DECR1495081 |
|
Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 5th Edition
5/11/2012 | published by: Kalorama Information
The drug discovery process is long, arduous and costly, which has driven outsourcing in this field. The first phase is discovery of a lead compound, a molecule that affects biological function by binding to a
|
more...
|
$3,995.00
|
|
Orphan Disease Therapeutics in Genetic Disorders to 2018 - Emerging Agents in Cystic Fibrosis Offer Strong Opportunities for Investment and Licensing Activity
5/15/2012 | published by: GBI Research
Orphan Disease Therapeutics in Genetic Disorders to 2018 - Emerging Agents in Cystic Fibrosis Offer Strong Opportunities for Investment and Licensing Activity
Summary
GBI Research, the leading
|
more...
|
$3,500.00
|
|
Retinal Vein Occlusion Therapeutics - Pipeline Assessment and Market Forecasts to 2019
5/21/2012 | published by: GlobalData
Retinal Vein Occlusion Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Summary GlobalData, the industry analysis specialist, has released its new report, “Retinal Vein Occlusion Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report
|
more...
|
$3,995.00
|
|
Hepatic Insufficiency Global Clinical Trials Review, H1, 2012
4/25/2012 | published by: GlobalData
Hepatic Insufficiency Global Clinical Trials Review, H1, 2012 Summary GlobalData's clinical trial report, “Hepatic Insufficiency Global Clinical Trials Review, H1, 2012 provides data on the Hepatic Insufficiency clinical trial scenario. This report provides elemental information and data
|
more...
|
$1,000.00
|
|
Orphan Diseases Therapeutics in Oncology to 2018 - Strongly Diversified Developmental Pipelines Indicate Long-Term Growth Potential despite Moderate Scope of Current Late Stage Molecules
4/30/2012 | published by: GBI Research
Orphan Diseases Therapeutics in Oncology to 2018 - Strongly Diversified Developmental Pipelines Indicate Long-Term Growth Potential despite Moderate Scope of Current Late Stage Molecules Summary GBI Research, the leading business intelligence provider, has released its latest research
|
more...
|
$3,500.00
|
|
Lung Injury Global Clinical Trials Review, H1, 2012
4/25/2012 | published by: GlobalData
Lung Injury Global Clinical Trials Review, H1, 2012 Summary GlobalData's clinical trial report, “Lung Injury Global Clinical Trials Review, H1, 2012 provides data on the Lung Injury clinical trial scenario. This report provides elemental information and data
|
more...
|
$1,000.00
|
|
Autoimmune Disorders Therapeutics Market to 2017 - Launch of Gilenya and Benlysta to Drive the Growth of Multiple Sclerosis and Systemic Lupus Erythematosus Therapeutic Segments
4/30/2012 | published by: GBI Research
Autoimmune Disorders Therapeutics Market to 2017 - Launch of Gilenya and Benlysta to Drive the Growth of Multiple Sclerosis and Systemic Lupus Erythematosus Therapeutic Segments Summary GBI Research, the leading business intelligence provider, has released its latest
|
more...
|
$3,500.00
|
|
Oral Drug Delivery Market to 2017 - Out-licensing Proprietary Technologies for Proteins, Peptides and Small Molecules to Drive Revenue Growth
4/30/2012 | published by: GBI Research
Oral Drug Delivery Market to 2017 - Out-licensing Proprietary Technologies for Proteins, Peptides and Small Molecules to Drive Revenue Growth Summary GBI Research, the leading business intelligence provider, has released its latest research “Oral Drug Delivery Market
|
more...
|
$3,500.00
|
|
Hepatic Encephalopathy Global Clinical Trials Review, H1, 2012
4/25/2012 | published by: GlobalData
Hepatic Encephalopathy Global Clinical Trials Review, H1, 2012 Summary GlobalData's clinical trial report, “Hepatic Encephalopathy Global Clinical Trials Review, H1, 2012 provides data on the Hepatic Encephalopathy clinical trial scenario. This report provides elemental information and data
|
more...
|
$1,000.00
|
|
Pulmonary Arterial Hypertension – Pipeline Review, H1 2012
4/19/2012 | published by: Global Markets Direct
Pulmonary Arterial Hypertension – Pipeline Review, H1 2012 Summary Global Markets Direct’s, 'Pulmonary Arterial Hypertension - Pipeline Review, H1 2012', provides an overview of the Pulmonary Arterial Hypertension therapeutic pipeline. This report provides information on the therapeutic
|
more...
|
$500.00
|
Related Markets
Drug Discovery Reports
- Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 5th Edition
- Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H1, 2012
- Tachycardia (Tachyarrhythmias) Global Clinical Trials Review, H1, 2012
- Restless Legs Syndrome Global Clinical Trials Review, H1, 2012
- Lung Injury Global Clinical Trials Review, H1, 2012
